Maven Securities’s IGM Biosciences IGMS Stock Holding History

Maven Securities’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,800	Closed	-$229K	–	1155
2023 Q2	$229K	Buy	+24,800	New	+$278K	﹤0.01%	796

Other funds holding IGMS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Maven Securities's IGMS Position: Q3 2023 in Review

Maven Securities sold out of IGM Biosciences (IGMS) in Q3 2023, closing a stake of 24,800 shares — an estimated $229K sold.

Maven Securities first reported a position in IGMS in Q2 2023 and held it in 1 quarter. The position peaked at $229K in Q2 2023. 79 funds tracked by Wall St. Rank hold IGMS as of Q3 2023.

Maven Securities reported no remaining IGM Biosciences position as of Q3 2023 after selling out during the quarter.
Maven Securities sold 24,800 IGM Biosciences shares in Q3 2023, an estimated $229K.
Maven Securities first reported a position in IGM Biosciences in Q2 2023 and held it in 1 quarter.
Maven Securities's IGM Biosciences position peaked at $229K in Q2 2023.
79 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2023.

Based on Maven Securities's 13F filing for Q3 2023, filed 13 Nov 2023.